Skip to content
Overview
About Us
Board of Directors
Committee
Investors
Investors Contact
Details of Company Secretary and Compliance Officer
Details of Registrar and Share Transfer Agent
IPO
Financials
Draft Prospectus
Addendum
Prospectus
Newspaper Advertisement
Pre-issue Advertisement
Post-issue Advertisement
Pre Issue Shareholding Pattern
Material Contacts and Documents
Material Contracts
Material Doucments
Disclosure under Reg 46 as per SEBI (LODR)
Policies
Financial Information and Annual Return
2023
Annual Report
Annual Return
Form AOC-4
Form MGT-7A
2024
Annual Report
Annual Return
Form AOC-4
Form MGT-7A
2025
Annual Report
Annual Return
Form AOC-4
Form MGT-7A
Stock Exchange Communication
F.Y 2026-27
Q1 – Quarter starting from 1st April to 30th June
Q2- Quarter starting from 1st July to 30th September
Q3- Quarter starting from 1st October to 31st December
Q4- Quarter starting from 1st January to 31st March
Shareholding Pattern
F.Y 2026-27
H1 – 1st April to 30th September
H2- 1st October to 31st March
Contact
X
BETABIOPHARM
Policies
1. Annual Evaluation Policy for Board of Directors
2. Code of Conduct
3. CSR Policy
4. Details of Familiarisation Programme for Independent Directors
5. Insider Trading
6. Material Subsidiaries
7. NRC Policy. Remuneration Policy for Directors
8. Preservation of Documents Policy
9. Policy on Materiality of Related Party Transactions
10. Risk Management Policy
11. Sexual Harassment Policy
12. Terms and Conditions of Appointment of Independent Directors
13. Whistle Blower Policy
14. Dividend Policy
15. Policy for Orderly Succession of Board of Directors and Senior Management
17. Determination of Material Events
18. Archival Policy
19. Anti-Corruption and Anti-Bribery Policy
